Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients

Annals of the Rheumatic Diseases

Volumn 68, Issue 12, 2009, Pages 1894-1897

  Genovese, M C ^a   Breedveld, F C ^b   Emery, P ^c   Cohen, S ^d   Keystone, E ^e   Matteson, E L ^f   Baptiste, Y ^g   Chai, A ^h   Burke, L ^g   Reiss, W ^h   Sweetser, M ⁱ   Shaw, T M ^g  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d METROPLEX CLINICAL RESEARCH CENTER   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f MAYO CLINIC   (United States)

^g ROCHE PRODUCTS LTD   (United Kingdom)

^h GENENTECH INC   (United States)

ⁱ BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; RITUXIMAB; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BACTERIAL ARTHRITIS; BRONCHITIS; CELLULITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE SEVERITY; DIVERTICULITIS; DRUG SAFETY; ERYSIPELAS; FEMALE; FOLLOW UP; GASTROENTERITIS; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; URINARY TRACT INFECTION; VIRUS MENINGITIS; WOUND INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTE SUBSETS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67651120559     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.101675     Document Type: Article

References (12)

1. Symmons DP, Jones MA, Scott DL, et al. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998;25:1072-1077
2. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-2293
3. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581 (Pubitemid 38758544)
4. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-1400
5. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806 (Pubitemid 44497758)
6. van Vollenhoven RF, Emery P, Bingham CO, et al. Extended follow-up of the longterm safety of rituximab in rheumatoid arthritis. Ann Rheum Dis 2007;66:88.
7. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-3908 (Pubitemid 350262316)
8. Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007;46:1191-1199 (Pubitemid 47053782)
9. Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-2904 (Pubitemid 47502735)
10. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007;66:228-234 (Pubitemid 46226059)
11. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-1419 (Pubitemid 38608062)
12. Genovese MC, Breedveld FC, Emery P, et al. Safety of TNF inhibitors and nonbiologic DMARDs in rheumatoid arthritis patients previously treated with rituximab. Arthritis Rheum 2007;58:262.